 Connection
Theresa Medina to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications Theresa Medina has written about Antineoplastic Combined Chemotherapy Protocols.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.253 |
|
|
|
-
Lorigan P, Medina TM, Nyakas M, Rutten A, Feun LG, Cowey CL, Payne M, Hussain I, Kuzel T, O'Day S, Sheri A, Friedlander PA, Kumar S, Bergersen VS, Foss Ø, Ellingsen EB, Bjørheim J, Bechter OE. The telomerase vaccine UV1 combined with ipilimumab and nivolumab versus ipilimumab and nivolumab in advanced melanoma (INITIUM): A randomized open-label phase 2 study. Eur J Cancer. 2026 Jan 17; 233:116162.
Score: 0.116
-
Milhem MM, Wise-Draper TM, Chandra S, Hanna GJ, Laux DE, Medina TM, Ansstas G, Daud A, Kelly CM, O'Day SJ, Perez CA, Wong MK, Friedlander PA, Kristedja TS, Burgess MA, Cowey CL, Hanks BA, Weight RM, Daniel WL, Feltner DE, Mix S, Sindelar L, Bexon AS, Bexon MF, Michel RE, Bhatia S. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors. J Immunother Cancer. 2025 Jul 25; 13(7).
Score: 0.113
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|